Eureka Therapeutics Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
2ndary - Private
- Investors
-
4
Eureka Therapeutics General Information
Description
Developer of T-cell immunotherapy platforms designed for the treatment of solid tumors and other malignancies. The company's platforms, including ARTEMIS and E-Alpha, utilize proprietary antibody discovery and T-cell receptor engineering technologies to access cancer-specific targets, enabling healthcare providers to harness the immune system for more effective cancer treatments.
Contact Information
Website
www.eurekatherapeutics.comCorporate Office
- 5858 Horton Street
- Suite 370
- Emeryville, CA 94608
- United States
Corporate Office
- 5858 Horton Street
- Suite 370
- Emeryville, CA 94608
- United States
Eureka Therapeutics Timeline
Eureka Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | 01-Jun-2026 | Completed | Clinical Trials - Phase 1 | |||
| 8. Grant | 06-Jun-2023 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 16-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series E) | 23-Jan-2020 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC | 15-Jun-2018 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series D) | 22-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series C) | 20-Aug-2014 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series B) | 17-Nov-2008 | $3.13M | $4.8M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 11-Jun-2007 | $1.67M | $1.67M | Completed | Startup |
Eureka Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 10,591,690 | $0.000100 | 8% | $0.3 | $0.3 | 1x | $0.3 | 12.76% |
| Series A | 8,341,270 | $0.000100 | 8% | $0.2 | $0.2 | 1x | $0.2 | 10.05% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Eureka Therapeutics Comparisons
Industry
Financing
Details
Eureka Therapeutics Competitors (57)
One of Eureka Therapeutics’s 57 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Genelux | Formerly VC-backed | Westlake Village, CA | ||||
| Oxford Biotherapeutics | Private Equity-Backed | Oxford, United Kingdom | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE |
Eureka Therapeutics Patents
Eureka Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025145059-A1 | Constructs targeting msln ecd and uses thereof | Inactive | 29-Dec-2023 | ||
| WO-2025145063-A1 | Constructs targeting msln peptide/mhc complexes and uses thereof | Inactive | 29-Dec-2023 | ||
| WO-2025145087-A1 | Constructs targeting msln peptide/mhc complexes and uses thereof | Inactive | 29-Dec-2023 | ||
| WO-2025096433-A1 | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof | Inactive | 30-Oct-2023 | ||
| EP-4661902-A1 | Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof | Pending | 06-Feb-2023 | C07K16/3038 |
Eureka Therapeutics Signals
Eureka Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| California Institute for Regenerative Medicine | Government | |||
| Maxpro Ventures | Venture Capital | Minority | ||
| Acorn Campus Taiwan | Venture Capital | Minority | ||
| Lyell Immunopharma | Corporation | Minority |
Eureka Therapeutics Investments (1)
Eureka Therapeutics’s most recent deal was a Joint Venture with Aeon Therapeutics. The deal was made on 01-Jan-2002.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aeon Therapeutics | 01-Jan-2002 | Joint Venture | Drug Discovery |
Eureka Therapeutics FAQs
-
When was Eureka Therapeutics founded?
Eureka Therapeutics was founded in 2006.
-
Where is Eureka Therapeutics headquartered?
Eureka Therapeutics is headquartered in Emeryville, CA.
-
What is the size of Eureka Therapeutics?
Eureka Therapeutics has 46 total employees.
-
What industry is Eureka Therapeutics in?
Eureka Therapeutics’s primary industry is Drug Discovery.
-
Is Eureka Therapeutics a private or public company?
Eureka Therapeutics is a Private company.
-
What is Eureka Therapeutics’s current revenue?
The current revenue for Eureka Therapeutics is .
-
How much funding has Eureka Therapeutics raised over time?
Eureka Therapeutics has raised $171M.
-
Who are Eureka Therapeutics’s investors?
California Institute for Regenerative Medicine, Maxpro Ventures, Acorn Campus Taiwan, and Lyell Immunopharma have invested in Eureka Therapeutics.
-
Who are Eureka Therapeutics’s competitors?
CytomX Therapeutics, Marengo Therapeutics, Genelux, Oxford Biotherapeutics, and Ayala Pharmaceuticals are some of the 57 competitors of Eureka Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process